GENinCode has a significant addressable market in the risk assessment and diagnosis of cardiovascular disease. There are already initial sales for the diagnostic products, but the company needs to show that it can build up demand in other markets, particularly the US.
The autumn should bring news about progress with FDA approval. That could boost the share price.
The shares did not get off to a good start and the price has fallen to 36.7p (36.4p/37p). That is despite positive news about c...
You are unauthorized to view this page.